Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ipsen Seeks Success Outside Big Pharma's Hunting Grounds

Keen On Drugs With Peak Sales Of $300m-800m

02 Mar 2022

• By Kevin Grogan

David Loew — David Loew • Source: Ipsen

Related Content

Ipsen To Exit Consumer Health And Focus On Specialty Pharma

11 Feb 2022

CymaBay Builds Seladelpar Case In PBC, But Door Not Closed On NASH

30 Jun 2021

Ipsen Targets External Innovation With Exicure Option In Rare Neurodegenerative Disorders

03 Aug 2021

Ipsen Gives Genfit Liver Drug New Lease Of Life

17 Dec 2021

Ipsen Positive On Palovarotene Despite Troubled Past

11 Dec 2020

Related Companies

Ipsen SA

Sanofi Pasteur

Clementia Pharmaceuticals, Inc.

Roche Holding AG

BAKX Therapeutics Inc.

Exicure, Inc.

Genfit SA

Intercept Pharmaceuticals, Inc.

Mayoly-Spindler SAS

Novartis AG

Additional Topics

Business Strategies Deals Leadership Commercial Rare Diseases Cancer BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.